EUVIMEDEUVIMED entdecken
Crossref

miRNome Profiling Analysis Reveals Novel Hepatocellular Carcinoma Diagnostic, Prognostic and Treatment-Related Candidate Biomarkers: Post hoc Analysis of SORAMIC Trial

Egidijus Morkunas, Evelina Vaitkeviciute, Ruta Inciuraite, Juozas Kupcinskas, Alexander Link, Jurgita Skieceviciene, Marianna Alunni-Fabbroni, Kerstin Schütte, Peter Malfertheiner, Greta Varkalaite, Jens Ricke

Digestive Diseases · 2024 · 42 (4) · 336-348

DOI: 10.1159/000538757 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases, online erschienen am 24.04.2024. Verfasst von Egidijus Morkunas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Digestive Research and Department of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, Sorafenib. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Early diagnosis of hepatocellular carcinoma (HCC) as well as evaluation of prognosis and prediction of treatment efficacy remains challenging due to the missing specific non-invasive biomarkers. The aim of this study was to identify disease-specific microRNA (miRNA) patterns for diagnosis, prediction of prognosis, and treatment response in patients with HCC.

Methods

The study population included 42 HCC patients from SORAMIC clinical trial: 22 patients received sorafenib monotherapy, 20 patients underwent 90Y radioembolization in combination with sorafenib. 20 individuals were included in the control group. HCC patients underwent collection of plasma samples before and 7–9 weeks after the beginning of the treatment. Isolation of circulating miRNAs, preparation of small RNA sequencing libraries and next-generation sequencing were performed. Association analysis for novel diagnostic, prognostic, and treatment-related candidate biomarkers was performed.

Results

A total of 42 differentially expressed (16 up-regulated and 26 down-regulated) miRNAs were identified comparing baseline and control group plasma samples. hsa-miR-215-5p and hsa-miR-192-5p were down-regulated, while hsa-miR-483-5p and hsa-miR-23b-3p were up-regulated comparing baseline and 7–9 weeks post-sorafenib monotherapy samples. hsa-miR-215-5p was the sole down-regulated miRNA in the same combination therapy comparison. hsa-miR-183-5p, hsa-miR-28-3p, and hsa-miR-1246 were found to be significantly up-regulated comparing non-responders versus responders to sorafenib. High hsa-miR-215-5p expression was significantly associated with worse HCC patients’ prognosis.

Conclusions

Systematic miRNA profiling of highly characterized samples from SORAMIC study revealed a subset of potential miRNA biomarkers for HCC diagnosis and prognosis of sorafenib-treated patients’ survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorSorafenibMicroRNAsHumansFemaleMalePrognosisMiddle AgedGene Expression ProfilingAgedAntineoplastic Agents

Stichwörter der Autor:innen

Hepatocellular carcinomaMicro RNASelective internal radiation therapySorafenib

Substanzen

Biomarkers, TumorSorafenibMicroRNAsAntineoplastic Agents

Autor:innen und Institutionen

  • Institute for Digestive Research and Department of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, Magdeburg, Germany.
  • Department of Radiology, University Hospital, LMU Munich, Munich, Germany.
  • Department of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken Marienhospital, Osnabrück, Germany.
  • Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.

Zitieren

APA

Morkunas, E., Vaitkeviciute, E., Inciuraite, R., Kupcinskas, J., Link, A., Skieceviciene, J., Alunni-Fabbroni, M., Schütte, K., Malfertheiner, P., Varkalaite, G., & Ricke, J. (2024). miRNome Profiling Analysis Reveals Novel Hepatocellular Carcinoma Diagnostic, Prognostic and Treatment-Related Candidate Biomarkers: Post hoc Analysis of SORAMIC Trial. Digestive Diseases, 42(4), 336-348. https://doi.org/10.1159/000538757

Vancouver

Morkunas E, Vaitkeviciute E, Inciuraite R, Kupcinskas J, Link A, Skieceviciene J, et al. miRNome Profiling Analysis Reveals Novel Hepatocellular Carcinoma Diagnostic, Prognostic and Treatment-Related Candidate Biomarkers: Post hoc Analysis of SORAMIC Trial. Digestive Diseases. 2024;42(4):336-348. doi:10.1159/000538757

BibTeX
@article{Morkunas2024,
  author = {Morkunas, Egidijus and Vaitkeviciute, Evelina and Inciuraite, Ruta and Kupcinskas, Juozas and Link, Alexander and Skieceviciene, Jurgita and Alunni-Fabbroni, Marianna and Schütte, Kerstin and Malfertheiner, Peter and Varkalaite, Greta and Ricke, Jens},
  title = {miRNome Profiling Analysis Reveals Novel Hepatocellular Carcinoma Diagnostic, Prognostic and Treatment-Related Candidate Biomarkers: Post hoc Analysis of SORAMIC Trial},
  journal = {Digestive Diseases},
  year = {2024},
  volume = {42},
  number = {4},
  pages = {336--348},
  doi = {10.1159/000538757}
}
Kostenlos starten →